Pictet Asset Management Holding SA Acquires Shares of 96,910 Centessa Pharmaceuticals PLC Sponsored ADR $CNTA

Pictet Asset Management Holding SA acquired a new position in shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) during the 1st quarter, Holdings Channel reports. The firm acquired 96,910 shares of the company’s stock, valued at approximately $3,849,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Caitong International Asset Management Co. Ltd bought a new stake in shares of Centessa Pharmaceuticals in the fourth quarter valued at about $80,000. T. Rowe Price Investment Management Inc. increased its position in Centessa Pharmaceuticals by 7,580.0% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,536 shares of the company’s stock worth $39,000 after acquiring an additional 1,516 shares during the period. Coastal Bridge Advisors LLC increased its position in Centessa Pharmaceuticals by 7.1% during the fourth quarter. Coastal Bridge Advisors LLC now owns 14,033 shares of the company’s stock worth $351,000 after acquiring an additional 931 shares during the period. XTX Topco Ltd acquired a new stake in Centessa Pharmaceuticals in the 4th quarter worth about $1,978,000. Finally, Voloridge Investment Management LLC bought a new stake in Centessa Pharmaceuticals in the 4th quarter valued at about $8,710,000. Institutional investors and hedge funds own 82.01% of the company’s stock.

Centessa Pharmaceuticals Stock Performance

CNTA opened at $40.50 on Friday. Centessa Pharmaceuticals PLC Sponsored ADR has a twelve month low of $12.74 and a twelve month high of $40.56. The company has a 50-day simple moving average of $39.85 and a 200 day simple moving average of $32.08. The company has a quick ratio of 9.53, a current ratio of 9.53 and a debt-to-equity ratio of 0.23. The stock has a market capitalization of $6.27 billion, a price-to-earnings ratio of -22.63 and a beta of 1.11.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.14). Analysts predict that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.65 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

CNTA has been the topic of a number of analyst reports. Truist Financial lowered shares of Centessa Pharmaceuticals from a “buy” rating to a “hold” rating and set a $38.00 target price on the stock. in a research report on Monday, April 13th. Wolfe Research downgraded shares of Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating in a research report on Tuesday, March 31st. Guggenheim cut Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, April 2nd. Wells Fargo & Company downgraded Centessa Pharmaceuticals from an “overweight” rating to an “equal weight” rating and increased their price target for the stock from $35.00 to $42.00 in a research report on Monday, April 20th. Finally, Needham & Company LLC downgraded Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, March 31st. Four investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $41.33.

Centessa Pharmaceuticals Profile

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.